Symbols / BOLD Stock $1.41 +1.44% Boundless Bio, Inc.

Healthcare • Biotechnology • United States • NMS
BOLD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Zachary D. Hornby
Exch · Country NMS · United States
Market Cap 31.67M
Enterprise Value -12.88M
Income -55.99M
Sales —
FCF (ttm) -30.52M
Book/sh 3.85
Cash/sh 4.13
Employees 28
Insider 10d —
IPO Mar 28, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.10
PEG —
P/S —
P/B 0.37
P/C —
EV/EBITDA 0.22
EV/Sales —
Quick Ratio 9.69
Current Ratio 9.87
Debt/Eq 55.90
LT Debt/Eq —
EPS (ttm) -2.49
EPS next Y -1.28
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-05-08
ROA -22.83%
ROE -50.22%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 22.46M
Shs Float 15.33M
Insider Own 11.35%
Instit Own 49.77%
Short Float 0.05%
Short Ratio 0.05
Short Interest 6.06K
52W High 1.68
vs 52W High -16.07%
52W Low 0.96
vs 52W Low 46.72%
Beta —
Impl. Vol. —
Rel Volume 0.04
Avg Volume 217.41K
Volume 9.72K
Target (mean) $4.00
Tgt Median $4.00
Tgt Low $4.00
Tgt High $4.00
# Analysts 1
Recom None
Prev Close $1.39
Price $1.41
Change 1.44%
About

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.00
Mean price target
2. Current target
$1.41
Latest analyst target
3. DCF / Fair value
$-24.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.41
Low
$4.00
High
$4.00
Mean
$4.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-11 main HC Wainwright & Co. Buy → Buy $4
2025-06-02 init HC Wainwright & Co. — → Buy $5
2025-05-28 down Leerink Partners Outperform → Market Perform $3
2024-12-13 down Guggenheim Buy → Neutral —
2024-04-22 init Leerink Partners — → Outperform $25
2024-04-22 init Guggenheim — → Buy $24
2024-04-22 init Piper Sandler — → Overweight $20
News
RSS: Latest BOLD news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
63.55
-13.26%
73.27
+33.71%
54.80
+17.92%
46.47
Research And Development
44.84
-18.86%
55.27
+29.62%
42.64
+14.74%
37.16
Selling General And Administration
18.71
+3.93%
18.00
+48.04%
12.16
+30.60%
9.31
General And Administrative Expense
18.71
+3.93%
18.00
+48.04%
12.16
+30.60%
9.31
Other Gand A
18.71
+3.93%
18.00
+48.04%
12.16
+30.60%
9.31
Total Expenses
63.55
-13.26%
73.27
+33.71%
54.80
+17.92%
46.47
Operating Income
-63.55
+13.26%
-73.27
-33.71%
-54.80
-17.92%
-46.47
Total Operating Income As Reported
-63.55
+13.26%
-73.27
-33.71%
-54.80
-17.92%
-46.47
EBITDA
-62.30
+13.69%
-72.18
-34.07%
-53.84
-18.26%
-45.53
Normalized EBITDA
-62.30
+13.69%
-72.18
-34.07%
-53.84
-18.26%
-45.53
Reconciled Depreciation
1.25
+15.19%
1.09
+13.48%
0.96
+1.59%
0.94
EBIT
-63.55
+13.26%
-73.27
-33.71%
-54.80
-17.92%
-46.47
Net Income
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Pretax Income
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Net Non Operating Interest Income Expense
5.36
-32.12%
7.89
+49.41%
5.28
+690.72%
0.67
Net Interest Income
5.36
-32.12%
7.89
+49.41%
5.28
+690.72%
0.67
Interest Income Non Operating
5.36
-32.12%
7.89
+49.41%
5.28
+690.72%
0.67
Interest Income
5.36
-32.12%
7.89
+49.41%
5.28
+690.72%
0.67
Other Income Expense
-0.00
-116.67%
0.01
-85.00%
0.08
+180.00%
-0.10
Other Non Operating Income Expenses
-0.00
-116.67%
0.01
-85.00%
0.08
+180.00%
-0.10
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Net Income From Continuing Operation Net Minority Interest
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Net Income From Continuing And Discontinued Operation
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Net Income Continuous Operations
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Normalized Income
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Net Income Common Stockholders
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Diluted EPS
-2.60
+32.47%
-3.85
-73.20%
-2.22
+32.25%
-3.28
Basic EPS
-2.60
+32.47%
-3.85
-73.20%
-2.22
+32.25%
-3.28
Basic Average Shares
22.36
+31.65%
16.98
-23.63%
22.24
+58.97%
13.99
Diluted Average Shares
22.36
+31.65%
16.98
-23.63%
22.24
+58.97%
13.99
Diluted NI Availto Com Stockholders
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
157.06
-23.91%
206.41
+58.91%
129.89
+69.07%
76.83
Current Assets
109.61
-29.00%
154.39
+24.30%
124.20
+82.55%
68.04
Cash Cash Equivalents And Short Term Investments
107.58
-29.28%
152.11
+25.97%
120.75
+80.99%
66.72
Cash And Cash Equivalents
17.87
-32.79%
26.59
+12.15%
23.71
+116.47%
10.95
Other Short Term Investments
89.71
-28.53%
125.53
+29.35%
97.05
+74.02%
55.77
Other Current Assets
2.03
-10.81%
2.28
-34.07%
3.45
+161.52%
1.32
Total Non Current Assets
47.45
-8.79%
52.02
+814.22%
5.69
-35.28%
8.79
Net PPE
46.88
-8.73%
51.36
+1022.62%
4.58
-40.78%
7.73
Gross PPE
51.84
-5.87%
55.07
+654.16%
7.30
-23.44%
9.54
Accumulated Depreciation
-4.96
-33.73%
-3.71
-36.01%
-2.73
-50.58%
-1.81
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.75
+1.40%
2.71
+173.84%
0.99
+19.85%
0.83
Other Properties
48.03
-6.51%
51.38
+719.93%
6.27
-27.69%
8.66
Leases
1.05
+7.44%
0.98
+2032.61%
0.05
+0.00%
0.05
Investments And Advances
—
—
—
0.00
Other Non Current Assets
0.57
-13.05%
0.66
-40.90%
1.11
+4.60%
1.07
Total Liabilities Net Minority Interest
58.41
+4.73%
55.77
-78.30%
256.98
+62.10%
158.53
Current Liabilities
12.54
+54.11%
8.13
-13.08%
9.36
+21.11%
7.73
Payables And Accrued Expenses
6.73
+25.64%
5.35
+25.50%
4.27
+50.32%
2.84
Payables
1.49
+17.03%
1.27
-42.66%
2.22
+58.49%
1.40
Accounts Payable
1.49
+17.03%
1.27
-42.66%
2.22
+58.49%
1.40
Current Accrued Expenses
5.24
+28.33%
4.08
+99.61%
2.04
+42.34%
1.44
Pensionand Other Post Retirement Benefit Plans Current
2.64
-4.96%
2.78
-4.04%
2.90
+17.85%
2.46
Current Debt And Capital Lease Obligation
3.17
—
2.19
-6.12%
2.34
Current Capital Lease Obligation
3.17
0.00
-100.00%
2.19
-6.12%
2.34
Other Current Liabilities
—
—
—
0.09
Total Non Current Liabilities Net Minority Interest
45.87
-3.70%
47.63
-80.76%
247.62
+64.21%
150.80
Long Term Debt And Capital Lease Obligation
45.87
-3.70%
47.63
0.00
-100.00%
2.85
Long Term Capital Lease Obligation
45.87
-3.70%
47.63
0.00
-100.00%
2.85
Other Non Current Liabilities
—
—
—
0.01
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
247.62
+67.37%
147.95
Stockholders Equity
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Common Stock Equity
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Capital Stock
0.00
+0.00%
0.00
0.00
0.00
Common Stock
0.00
+0.00%
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
22.41
+0.48%
22.30
+0.27%
22.24
+0.00%
22.24
Ordinary Shares Number
22.41
+0.48%
22.30
+0.27%
22.24
+0.00%
22.24
Additional Paid In Capital
358.26
+1.78%
351.99
+3816.67%
8.99
+67.14%
5.38
Retained Earnings
-259.67
-28.89%
-201.47
-48.02%
-136.11
-57.03%
-86.67
Gains Losses Not Affecting Retained Earnings
0.06
-47.11%
0.12
+202.50%
0.04
+110.05%
-0.40
Other Equity Adjustments
0.06
-47.11%
0.12
+202.50%
0.04
+110.05%
-0.40
Total Equity Gross Minority Interest
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Total Capitalization
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Working Capital
97.07
-33.63%
146.25
+27.35%
114.84
+90.43%
60.31
Invested Capital
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Total Debt
49.03
+2.95%
47.63
+2070.02%
2.19
-57.65%
5.18
Capital Lease Obligations
49.03
+2.95%
47.63
+2070.02%
2.19
-57.65%
5.18
Net Tangible Assets
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Tangible Book Value
98.65
-34.51%
150.64
+218.54%
-127.08
-55.55%
-81.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-46.66
+23.31%
-60.84
-29.85%
-46.85
-18.33%
-39.60
Cash Flow From Continuing Operating Activities
-46.66
+23.31%
-60.84
-29.85%
-46.85
-18.33%
-39.60
Net Income From Continuing Operations
-58.20
+10.96%
-65.36
-32.22%
-49.43
-7.70%
-45.90
Depreciation Amortization Depletion
1.25
+15.19%
1.09
+13.48%
0.96
+1.59%
0.94
Depreciation
—
—
0.96
+1.59%
0.94
Depreciation And Amortization
1.25
+15.19%
1.09
+13.48%
0.96
+1.59%
0.94
Other Non Cash Items
3.29
+23.94%
2.65
+11.24%
2.38
+39.96%
1.70
Stock Based Compensation
6.12
-18.51%
7.52
+125.30%
3.34
+45.68%
2.29
Change In Working Capital
3.46
+306.32%
-1.68
-110.01%
-0.80
-192.26%
0.87
Change In Prepaid Assets
0.33
+209.93%
-0.30
-455.29%
0.09
-60.83%
0.22
Change In Payables And Accrued Expense
1.63
+110.84%
0.78
-53.40%
1.66
-12.98%
1.91
Change In Other Current Liabilities
1.50
+169.55%
-2.15
+15.55%
-2.55
-101.82%
-1.26
Investing Cash Flow
37.80
+244.83%
-26.10
+31.78%
-38.26
-337.17%
16.13
Cash Flow From Continuing Investing Activities
37.80
+244.83%
-26.10
+31.78%
-38.26
-337.17%
16.13
Net PPE Purchase And Sale
-0.55
+78.47%
-2.54
-300.63%
-0.63
+40.62%
-1.07
Purchase Of PPE
-0.55
+78.47%
-2.54
-300.63%
-0.63
+40.62%
-1.07
Capital Expenditure
-0.55
+78.47%
-2.54
-300.63%
-0.63
+40.62%
-1.07
Net Investment Purchase And Sale
38.35
+262.73%
-23.57
+37.37%
-37.63
-318.79%
17.20
Purchase Of Investment
-174.90
+16.10%
-208.47
-30.19%
-160.12
-275.89%
-42.60
Sale Of Investment
213.24
+15.33%
184.90
+50.94%
122.50
+104.86%
59.80
Financing Cash Flow
0.14
-99.84%
89.82
-8.25%
97.90
+77596.03%
0.13
Cash Flow From Continuing Financing Activities
0.14
-99.84%
89.82
-8.25%
97.90
+77596.03%
0.13
Net Common Stock Issuance
0.00
-100.00%
93.00
0.00
—
Proceeds From Stock Option Exercised
0.14
-18.02%
0.17
-5.49%
0.18
+44.44%
0.13
Net Other Financing Charges
—
-3.35
-71.22%
-1.96
—
Changes In Cash
-8.72
-402.64%
2.88
-77.46%
12.78
+154.77%
-23.34
Beginning Cash Position
27.15
+11.87%
24.27
+111.30%
11.48
-67.02%
34.82
End Cash Position
18.43
-32.12%
27.15
+11.87%
24.27
+111.30%
11.48
Free Cash Flow
-47.21
+25.51%
-63.38
-33.46%
-47.49
-16.79%
-40.66
Amortization Of Securities
-2.59
+48.76%
-5.05
-53.18%
-3.30
-756.06%
0.50
Common Stock Issuance
0.00
-100.00%
93.00
0.00
—
Issuance Of Capital Stock
0.00
-100.00%
93.00
-6.69%
99.67
0.00
Net Preferred Stock Issuance
—
0.00
-100.00%
99.67
0.00
Preferred Stock Issuance
—
0.00
-100.00%
99.67
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category